MaassenVanDenBrink A - Search Results

1

Neurogenic inflammation as a novel treatment target for chronic pain syndromes.

Seidel MF, Hügle T, Morlion B, Koltzenburg M, Chapman V, MaassenVanDenBrink A, Lane NE, Perrot S, Zieglgänsberger W. Seidel MF, et al. Among authors: maassenvandenbrink a. Exp Neurol. 2022 Oct;356:114108. doi: 10.1016/j.expneurol.2022.114108. Epub 2022 May 10. Exp Neurol. 2022. PMID: 35551902 Review.

2

Calcitonin-gene-related peptide pathway mAbs and migraine prevention.

Paemeleire K, MaassenVanDenBrink A. Paemeleire K, et al. Among authors: maassenvandenbrink a. Curr Opin Neurol. 2018 Jun;31(3):274-280. doi: 10.1097/WCO.0000000000000548. Curr Opin Neurol. 2018. PMID: 29432219 Review.

3

Sex Differences in Response to Triptans: A Systematic Review and Meta-analysis.

van Casteren DS, Kurth T, Danser AHJ, Terwindt GM, MaassenVanDenBrink A. van Casteren DS, et al. Among authors: maassenvandenbrink a. Neurology. 2021 Jan 26;96(4):162-170. doi: 10.1212/WNL.0000000000011216. Epub 2020 Nov 18. Neurology. 2021. PMID: 33208542

4

Drug interactions and risks associated with the use of triptans, ditans and monoclonal antibodies in migraine.

Al-Hassany L, MaassenVanDenBrink A. Al-Hassany L, et al. Among authors: maassenvandenbrink a. Curr Opin Neurol. 2021 Jun 1;34(3):330-338. doi: 10.1097/WCO.0000000000000932. Curr Opin Neurol. 2021. PMID: 33852525 Review.

5

Treatment with the monoclonal calcitonin gene-related peptide receptor antibody erenumab: A real-life study.

de Vries Lentsch S, Verhagen IE, van den Hoek TC, MaassenVanDenBrink A, Terwindt GM. de Vries Lentsch S, et al. Among authors: maassenvandenbrink a. Eur J Neurol. 2021 Dec;28(12):4194-4203. doi: 10.1111/ene.15075. Epub 2021 Sep 7. Eur J Neurol. 2021. PMID: 34424593 Free PMC article.

6

Calcitonin gene-related peptide-targeting drugs for migraine: how pharmacology might inform treatment decisions.

Al-Hassany L, Goadsby PJ, Danser AHJ, MaassenVanDenBrink A. Al-Hassany L, et al. Among authors: maassenvandenbrink a. Lancet Neurol. 2022 Mar;21(3):284-294. doi: 10.1016/S1474-4422(21)00409-9. Epub 2022 Jan 31. Lancet Neurol. 2022. PMID: 35093196 Review.

7

Blood Pressure in Patients With Migraine Treated With Monoclonal Anti-CGRP (Receptor) Antibodies: A Prospective Follow-up Study.

de Vries Lentsch S, van der Arend BWH, Maassen VanDenBrink A, Terwindt GM. de Vries Lentsch S, et al. Neurology. 2022 Oct 25;99(17):e1897-e1904. doi: 10.1212/WNL.0000000000201008. Epub 2022 Oct 4. Neurology. 2022. PMID: 36195452 Free PMC article.

8

Interictal cortical excitability to magnetic stimulation in familial hemiplegic migraine.

van der Kamp W, MaassenVanDenBrink A, Ferrari MD, van Dijk JG. van der Kamp W, et al. Among authors: maassenvandenbrink a. Neurology. 1997 May;48(5):1462-4. doi: 10.1212/wnl.48.5.1462. Neurology. 1997. PMID: 9153495

9

Current and prospective pharmacological targets in relation to antimigraine action.

Mehrotra S, Gupta S, Chan KY, Villalón CM, Centurión D, Saxena PR, MaassenVanDenBrink A. Mehrotra S, et al. Among authors: maassenvandenbrink a. Naunyn Schmiedebergs Arch Pharmacol. 2008 Oct;378(4):371-94. doi: 10.1007/s00210-008-0322-7. Epub 2008 Jul 15. Naunyn Schmiedebergs Arch Pharmacol. 2008. PMID: 18626630 Review.

10

Activation of 5-hydroxytryptamine1B/1D/1F receptors as a mechanism of action of antimigraine drugs.

Ramírez Rosas MB, Labruijere S, Villalón CM, Maassen Vandenbrink A. Ramírez Rosas MB, et al. Expert Opin Pharmacother. 2013 Aug;14(12):1599-610. doi: 10.1517/14656566.2013.806487. Epub 2013 Jul 2. Expert Opin Pharmacother. 2013. PMID: 23815106 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

197 results

Search Page

Filters